Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

STERNA Enzymatic STEreospecific RNA phosphorothioate modification for next-generation therapeutics

Coordinator
Weizmann Institute of Science, Israel
Runs
1 August 2026 to 31 January 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101331454

What the project is doing

In the project's own words, from its summary on CORDIS.

RNA therapeutics have emerged as a powerful medical modality, from COVID-19 vaccines to treatments for rare genetic diseases and cancer. However, a fundamental bottleneck limits their potential: RNA instability. Most approved RNA drugs rely on phosphorothioate (PS) modifications for stability and delivery, but current chemical synthesis produces stereochemical mixtures reducing efficacy, increasing toxicity, and complicating regulatory approval.

Moreover, chemical PS synthesis is restricted to short RNAs, completely excluding therapeutic mRNAs from site-specific backbone optimization despite evidence that strategic PS placement can dramatically enhance translation efficiency. This represents a fundamental technological gap constraining millions of patients with rare genetic diseases and cancer needing personalized immunotherapies from accessing safer and more effective RNA medicines.

Our ERC-funded discovery revealed the first naturally occurring stereospecific RNA PS modifications and the enzyme family responsible for their installation. This breakthrough provides a biological route to manufacturing next-generation RNA therapeutics, simultaneously eliminating stereochemical heterogeneity, enabling cost-effective stereopure synthesis (≥10x cheaper), and uniquely installing site-specific PS modifications in full-length mRNAs.

This PoC will advance our technology from TRL 3 to TRL 4 through three objectives targeting industrial readiness: 1) we will demonstrate scalable enzymatic PS installation to produce stereopure modified RNA, 2) we will engineer programmable substrate specificity to create variants targeting therapeutic ASOs and mRNAs and 3) we will demonstrate commercial feasibility through techno-economic analysis and engagement with RNA therapeutics companies.

Our success will address the unmet patient needs while unlocking market opportunities in the $6.5B ASO therapeutics and $11.4B mRNA therapeutics markets currently constrained by manufacturing limitations

Topics

Who is involved

OrganisationCityCountryRole
Weizmann Institute of ScienceRehovotIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI